Sam Brusco, Associate Editor03.23.21
Olympus Corporation of the Americas filed litigation in the U.S. District Court for the Southern District of Texas accusing Cantel/Medivators of violating patents related to colonoscopy assist devices.
The complaint alleges the manufacture, sale, and distribution of the AmplifEye Endoscopic Device infringes on two patents Olympus holds for its ENDOCUFF single-use devices. This lawsuit follows a High Court of Justice England and Wales, Patent Court finding the ENDOCUFF and ENDOCUFF VISION UK national and UK(EP) patents were infringed by the AmplifEye Endoscopic Device. The family of ENDOCUFF products and the patents protecting them were fully acquired in Olympus’ summer 2020 acquisition of Arc Medical Design. Olympus seeks an injunction against further U.S. sales of the violative product.
"The acquisition of Arc Medical Design included important intellectual property rights, valuable technology development and the investment of time and resources toward commercialization, all of which we intend to vigorously protect," Gael Tisack, Global Head of Intellectual Property for Olympus Corporation told the press. "We believe the injunction in the UK against sales of the infringing product, along with other evidence, bodes well for the Olympus case in the U.S."
The complaint alleges the manufacture, sale, and distribution of the AmplifEye Endoscopic Device infringes on two patents Olympus holds for its ENDOCUFF single-use devices. This lawsuit follows a High Court of Justice England and Wales, Patent Court finding the ENDOCUFF and ENDOCUFF VISION UK national and UK(EP) patents were infringed by the AmplifEye Endoscopic Device. The family of ENDOCUFF products and the patents protecting them were fully acquired in Olympus’ summer 2020 acquisition of Arc Medical Design. Olympus seeks an injunction against further U.S. sales of the violative product.
"The acquisition of Arc Medical Design included important intellectual property rights, valuable technology development and the investment of time and resources toward commercialization, all of which we intend to vigorously protect," Gael Tisack, Global Head of Intellectual Property for Olympus Corporation told the press. "We believe the injunction in the UK against sales of the infringing product, along with other evidence, bodes well for the Olympus case in the U.S."